Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-25-002451
Filing Date
2025-04-14
Accepted
2025-04-14 17:27:04
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8068
2 d11781412_ex99-a.htm EX-99 5545
3 d11781412_ex99-b.htm EX-99 977
  Complete submission text file 0000919574-25-002451.txt   16495
Mailing Address 152 WEST 57TH STREET 50TH FLOOR NEW YORK NY 10019
Business Address 152 WEST 57TH STREET 50TH FLOOR NEW YORK NY 10019 212-333-0100
KINGDON CAPITAL MANAGEMENT, L.L.C. (Filed by) CIK: 0001000097 (see all company filings)

EIN.: 134015739 | State of Incorp.: DE
Type: SCHEDULE 13G

Mailing Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067
Business Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067 267-364-3500
OptiNose, Inc. (Subject) CIK: 0001494650 (see all company filings)

EIN.: 421771610 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90169 | Film No.: 25836845
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)